Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
76.94
-0.20 (-0.26%)
Streaming Delayed Price
Updated: 2:27 PM EDT, Sep 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
September 11, 2022
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
September 11, 2022
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
September 09, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
September 05, 2022
From
AstraZeneca
Via
Business Wire
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
August 27, 2022
From
AstraZeneca
Via
Business Wire
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
August 27, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
August 24, 2022
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
August 16, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
August 12, 2022
From
AstraZeneca
Via
Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
August 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
The Power of Science to Stop a Killer
August 08, 2022
Via
Investor Brand Network
The Power of Science to Stop a Killer
August 08, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114...
Via
FinancialNewsMedia
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
August 08, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
August 05, 2022
From
AstraZeneca
Via
Business Wire
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
August 05, 2022
From
AstraZeneca
Via
Business Wire
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
July 25, 2022
From
AstraZeneca
Via
Business Wire
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Palm Beach, FL – July 18, 2022 – FinancialNewsMedia.com News Commentary – Particulate matter or particle pollution is a significant contributor to heart and lung disease. Individuals most affected by...
Via
FinancialNewsMedia
Topics
Climate Change
Emissions
Energy
Exposures
Climate
Fossil Fuels
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
July 01, 2022
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
June 30, 2022
From
AstraZeneca Pharmaceuticals
Via
Business Wire
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
June 23, 2022
From
Alexion
Via
Business Wire
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
June 21, 2022
From
AstraZeneca
Via
Business Wire
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
June 21, 2022
From
AstraZeneca
Via
Business Wire
Breakthroughs In Treating Killer Diseases Could Lengthen Life
June 07, 2022
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – According to the World Health Organization, top global killers include heart failure, COPD, cancers, Alzheimer’s, neonatal...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
June 05, 2022
From
AstraZeneca
Via
Business Wire
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
June 04, 2022
From
AstraZeneca
Via
Business Wire
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
May 27, 2022
From
AstraZeneca
Via
Business Wire
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
May 23, 2022
From
AstraZeneca
Via
Business Wire
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
May 15, 2022
From
AstraZeneca
Via
Business Wire
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
May 05, 2022
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.